Home Sulfos N-Methyl-n-(3-((2-(2-oxoindolin-5-ylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)methyl)pyridin-2-yl)methanesulfonamide benzenesulfonate

N-Methyl-n-(3-((2-(2-oxoindolin-5-ylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)methyl)pyridin-2-yl)methanesulfonamide benzenesulfonate

CAS No.:
939791-38-5
Catalog Number:
AG00GU5G
Molecular Formula:
C27H26F3N7O6S2
Molecular Weight:
665.6638
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥98%
1 week
United States
$97
- +
5mg
99%
1 week
United States
$173
- +
10mg
99%
1 week
United States
$207
- +
50mg
99%
1 week
United States
$473
- +
100mg
99%
1 week
United States
$807
- +
Product Description
Catalog Number:
AG00GU5G
Chemical Name:
N-Methyl-n-(3-((2-(2-oxoindolin-5-ylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)methyl)pyridin-2-yl)methanesulfonamide benzenesulfonate
CAS Number:
939791-38-5
Molecular Formula:
C27H26F3N7O6S2
Molecular Weight:
665.6638
MDL Number:
MFCD14105612
IUPAC Name:
benzenesulfonic acid;N-methyl-N-[3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]pyridin-2-yl]methanesulfonamide
InChI:
InChI=1S/C21H20F3N7O3S.C6H6O3S/c1-31(35(2,33)34)19-12(4-3-7-25-19)10-26-18-15(21(22,23)24)11-27-20(30-18)28-14-5-6-16-13(8-14)9-17(32)29-16;7-10(8,9)6-4-2-1-3-5-6/h3-8,11H,9-10H2,1-2H3,(H,29,32)(H2,26,27,28,30);1-5H,(H,7,8,9)
InChI Key:
LKLWTLXTOVZFAE-UHFFFAOYSA-N
SMILES:
OS(=O)(=O)c1ccccc1.O=C1Nc2c(C1)cc(cc2)Nc1ncc(c(n1)NCc1cccnc1N(S(=O)(=O)C)C)C(F)(F)F
Properties
Complexity:
1040  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
665.134g/mol
Formal Charge:
0
Heavy Atom Count:
45  
Hydrogen Bond Acceptor Count:
15  
Hydrogen Bond Donor Count:
4  
Isotope Atom Count:
0
Molecular Weight:
665.663g/mol
Monoisotopic Mass:
665.134g/mol
Rotatable Bond Count:
8  
Topological Polar Surface Area:
200A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120501
Properties